Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cadrenal Therapeutics, Inc. (CVKD : NSDQ)

• Company Description    Cadrenal Therapeutics Inc. is a biopharmaceutical company. It focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. Cadrenal Therapeutics Inc. is based in PONTE VEDRA, Fla. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $11.00 Daily Weekly Monthly 20 Day Moving Average: 39,476 shares Shares Outstanding: 2.08 (millions) Market Capitalization: $22.83 (millions) Beta: 1.08 52 Week High: $22.90 52 Week Low: $8.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.58% -6.82% 12 Week -17.54% -19.90% Year To Date -24.09% -35.30%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 822 A1A North Suite 306 - Ponte Vedra,FL 32082 USA ph: 904-300-0701 fax: - cadrenal@lythampartners.com http://www.cadrenal.com

• General Corporate Information    Officers Quang X. Pham - Chairman and Chief ExecutiveOfficer Matthew Szot - Chief Financial Officer John R. Murphy - Director Glynn Wilson - Director Steven Zelenkofske - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 127636207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/12/26 Share - Related Items Shares Outstanding: 2.08 Most Recent Split Date: 8.00 (0.07:1) Beta: 1.08 Market Capitalization: $22.83 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.21 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.37 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.23 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 39.91% vs. Previous Quarter: 29.95% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -279.50 06/30/25 - -265.37 03/31/25 - -244.94 ROA 09/30/25 - -204.46 06/30/25 - -196.38 03/31/25 - -181.94 Current Ratio 09/30/25 - 3.02 06/30/25 - 3.55 03/31/25 - 4.32 Quick Ratio 09/30/25 - 3.02 06/30/25 - 3.55 03/31/25 - 4.32 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 1.34 06/30/25 - 2.10 03/31/25 - 3.15 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©